Table 2 Disease characteristics and laboratory data of SLE and RA patients
Disease characteristics and laboratory data of SLE and RA patients | ||
|---|---|---|
| Â | SLE patients (n = 14) | RA patients (n = 12) |
Years since diagnosis, median (IQR) | 4.0 (0.8–7.8) | 5.5 (1.5–9.3) |
Medication | ||
 None, n (%) | 2 (14) | 3 (25) |
 Prednisone, n (%) | 1 (7) | 1 (8) |
 Prednisone + cDMARD, n (%) | 3 (21) | 1 (8) |
 Prednisone dose, mg/day, mean (SD) | 12.5 (2.0) | 7.5 (3.5) |
 Antimalarials, n (%) | 10 (71) | 0 (0) |
 Azathioprine, n (%) | 3 (21) | 0 (0) |
 Methotrexate, n (%) | 0 (0) | 8 (67) |
 Mycophenolate mofetil, n (%) | 2 (14) | 0 (0) |
Disease activity parameters | ||
 DAS28-ESR, median (IQR) |  | 2.5 (2.0–3.6) |
 SLEDAI-2k, median (IQR) | 2.0 (0.0–9.3) |  |
Clinical parameters | ||
 Extra-articular manifestations, n (%) |  | 1 (8.3%) |
SLEDAI-2k, organ system involvement, n (%) | ||
 CNS | 0 |  |
 Vascular | 0 |  |
 Musculoskeletal | 2 (14) |  |
 Renal | 2 (14) |  |
 Mucocutaneous | 3 (21) |  |
 Cardiovascular and respiratory | 2 (14) |  |
 Immunological | 10 (71) |  |
 Constitutional | 0 |  |
 Hematological | 1 (7) |  |
Laboratory parameters | ||
 RF positive, n (%) | 5 (39) | 10 (83) |
 Anti-CCP positive, n (%) | 0 | 12 (100) |
 ANA positive, n (%) | 14 (100) | 1 (11) |